Top Employer-Paid Stories
Eli Lilly joins Novo Nordisk in reducing GLP-1 costs by lowering Zepbound price
By Alan Goforth“Far too many people who need obesity treatments still face cost and coverage barriers,” said Ilya Yuffa, executive vice president of Lilly USA.





